-
公开(公告)号：US20160347717A1
公开(公告)日：2016-12-01
申请号：US15167373
申请日：2016-05-27
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Mark BOCK , Ming-Hong HAO , Manav KORPAL , Vijay Kumar NYAVANANDI , Xiaoling PUYANG , Susanta SAMAJDAR , Peter Gerard SMITH , John WANG , Guo Zhu ZHENG , Ping ZHU
IPC: C07D231/56 , C07D401/14 , C07D403/06 , C07D401/06 , C07D403/12 , C07D471/14
CPC classification number: C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
Abstract translation: 本文公开了化合物或其药学上可接受的盐，以及通过向有需要的受试者施用治疗有效量的化合物或其药学上可接受的盐来使用该化合物治疗乳腺癌的方法。 乳腺癌可能是ER阳性乳腺癌，和/或需要治疗的受试者可以表达突变型ER-α蛋白。
-
公开(公告)号：US20240360108A1
公开(公告)日：2024-10-31
申请号：US18581307
申请日：2024-02-19
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61K47/68 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
CPC classification number: C07D405/12 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/0011 , A61K39/3955 , A61K39/39558 , A61K45/06 , A61K47/60 , A61K47/6845 , A61K47/6849 , A61K47/6851 , A61K47/6857 , A61K47/6869 , A61K47/6871 , A61K47/6889 , A61P35/00 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/2803 , C07K16/2818 , C07K16/2827 , C07K16/2896 , C07K16/3007 , C07K16/3092 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/5011 , G01N33/574 , A61K2039/505 , A61K2039/53 , A61K2039/545 , C07K2317/565 , C07K2317/76 , C12Q2600/106 , G01N2500/10
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20210101888A1
公开(公告)日：2021-04-08
申请号：US17247117
申请日：2020-11-30
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: C07D405/12 , A61P35/00
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20180127378A1
公开(公告)日：2018-05-10
申请号：US15713107
申请日：2017-09-22
Applicant: Eisai R&D Management Co., Ltd.
Inventor： Mark BOCK , Ming-Hong HAO , Manav KORPAL , Vijay Kumar NYAVANANDI , Xiaoling PUYANG , Susanta SAMAJDAR , Peter Gerard SMITH , John WANG , Guo Zhu ZHENG , Ping ZHU
IPC: C07D231/56 , C07D401/14 , C07D403/12 , C07D403/06 , C07D471/14 , C07D401/06
CPC classification number: C07D231/56 , C07D401/06 , C07D401/14 , C07D403/06 , C07D403/12 , C07D471/14
Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
公开(公告)号：US20240350484A1
公开(公告)日：2024-10-24
申请号：US18645759
申请日：2024-04-25
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , James PALACINO , Michael SEILER , Ping ZHU , Evan BARRY , Lihua YU
IPC: A61K31/496 , A61K35/17 , A61K38/19 , A61K38/20 , A61K38/21 , A61K39/00 , A61K39/39 , A61K39/395
CPC classification number: A61K31/496 , A61K35/17 , A61K38/191 , A61K38/2013 , A61K38/2066 , A61K38/208 , A61K38/2086 , A61K38/217 , A61K39/0011 , A61K39/39 , A61K39/3955 , A61K2039/6031 , A61K2039/6037 , A61K2039/6056 , A61K2039/6081
Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
Patent Agency Ranking
公开(公告)号：US20210346371A1
公开(公告)日：2021-11-11
申请号：US17059876
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , James PALACINO , Michael SEILER , Ping ZHU , Evan BARRY , Lihua YU
IPC: A61K31/496 , A61K39/395 , A61K39/00 , A61K39/39 , A61K38/21 , A61K38/20 , A61K35/17 , A61K47/68 , A61K38/19
Abstract: This disclosure relates to methods for the treatment of neoplastic disorders by administering Compound 1, or a pharmaceutically acceptably salt thereof, on its own and/or as part of a conjugate or composition, and inducing production of at least one neoantigen.
-
公开(公告)号：US20210299269A1
公开(公告)日：2021-09-30
申请号：US17059635
申请日：2019-05-31
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong Xiao
IPC: A61K47/68 , C07K16/32 , C07K16/28 , C07K16/40 , A61K47/60 , C07D405/06 , A61P35/00 , G01N33/50 , C07D313/00 , A61K31/496 , A61K31/365 , A61K39/395 , A61K45/06 , A61K39/00 , A61K9/127 , A61K9/51 , C12Q1/6886 , G01N33/574 , C07K16/30 , C07K16/24
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20250135017A1
公开(公告)日：2025-05-01
申请号：US18830446
申请日：2024-09-10
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: A61K47/68 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , A61K47/60 , A61P35/00 , C07D313/00 , C07D405/06 , C07D405/12 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.
-
公开(公告)号：US20220380352A1
公开(公告)日：2022-12-01
申请号：US17661909
申请日：2022-05-03
Applicant: EISAI R&D MANAGEMENT CO., LTD.
Inventor： Ermira PAZOLLI , Silvia BUONAMICI , Thiwanka SAMARAKOON , Sudeep PRAJAPATI , Nathan FISHKIN , James PALACINO , Michael SEILER , Ping ZHU , Andrew COOK , Peter SMITH , Xiang LIU , Shelby ELLERY , Dominic REYNOLDS , Lihua YU , Zhenhua WU , Shouyong PENG , Nicholas CALANDRA , Megan SHEEHAN , Yonghong XIAO
IPC: C07D405/12 , A61P35/00 , A61K47/68 , A61K47/60 , A61K9/127 , A61K9/51 , A61K31/365 , A61K31/496 , A61K39/00 , A61K39/395 , A61K45/06 , C07D313/00 , C07D405/06 , C07K16/24 , C07K16/28 , C07K16/30 , C07K16/32 , C07K16/40 , C12Q1/6886 , G01N33/50 , G01N33/574
Abstract: Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein. In an embodiment, the splicing modulator comprises a pladienolide or a pladienolide derivative.
-
公开(公告)号：US20180141913A1
公开(公告)日：2018-05-24
申请号：US15821367
申请日：2017-11-22
Applicant: EISAI R & D MANAGEMENT CO., LTD.
Inventor： Mark BOCK , Ming-Hong HAO , Manav KORPAL , Vijay Kumar NYAVANANDI , Xiaoling PUYANG , Susanta SAMAJDAR , Peter Gerard SMITH , John WANG , Guo Zhu ZHENG , Ping ZHU , Lorna Helen MITCHELL , Nicholas LARSEN , Nathalie RIOUX , Sudeep PRAJAPATI , Dominic REYNOLDS , Morgan O'SHEA , Thiwanka SAMARAKOON
IPC: C07D231/56 , C07D401/14 , C07D401/10 , C07D413/12 , C07D413/14 , A61P35/00
CPC classification number: C07D231/56 , A61P35/00 , C07D401/06 , C07D401/10 , C07D401/14 , C07D403/12 , C07D413/12 , C07D413/14
Abstract: Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.019 seconds)
